Which biomarker(s) are best suited to overcome current MRI interpretive issues and poor specificity in monitoring the effective response to therapy and the prediction of ARIA events? Irrespective of current legit debates on the clinical efficacy of amyloid-lowering therapeutics, several monoclonal antibodies… Read more (mAbs) are currently in clinical trials pipeline , including anti-TREM2 antagoist mAbs, or have entered accelerated FDA approval pathway. This means that 3 to 4 mAbs could potentially enter clinical practice in 2023. However, all of these high plaque-removing mAbs reported a common dose- and time-dependent incidence of ARIAs in up to 55% of the treated patients. In this framework, in order to minimize the risk of ARIAs, current trials limit enrollment to an extremely well-selected and radiographically monitored subpopulation of AD patients. Common criteria are the exclusion of patients with =5 cerebral microbleeds or cortical superficial siderosis at baseline and a control MRI before each biweekly/monthly infusion. This issue is challanging the generalizability of trials results, in particular concerning potential increased safety issues in real-word clinical settings. With 139 million of AD esteemed by 2050, and 60% of them living in low- and middle-income countries (2021 WHO report), longitudinal MRI monitoring plans for ARIA will hugely affect healthcare systems. This will potentially increase disparities, limiting accessibility to these therapeutics only to reach people and countries. In this framework, less costly and more accessible biomarkers will be of paramount importance for the future of AD immunotherapy. The UNIMIB-ARIA Toolkit Project aims at: 1) increase knowledge on the emerging evidence for neuroinflammation in the pathophysiology of ARIAs. 2) validate fluid-based biomarkers for improving diagnosis, prognosis, response to treatment, and prediction of ARIA-E recurrence compared to current state-of-the-art MRI images markers Thanks to the capillary activity and promotion we did in the last 10 years, including educational activities, at UNIMIB we are the National HUB for CAA and CAA-ri, receiving patients from almost all the main National centers (Spokes), the latter working as sub-spokes at regional and sub-regional level, in order to catch any patient also from very remote and rural areas. For these reasons, the National (Italy) biorepository should be considered an extremely excellent representation of the real-world clinical setting of the whole country. A gender-balanced Team (50% Female, 50% Male) of self-motivated and enthusiastic early career and young researcher composes the Teamwork. Addressing the aims of the UNIMIB-ARIA Project will be of paramount importance to increase generalizability and limit unnecessary restrictions to the future access of AD Therapeutics by the broaden community of AD and CAA patients, as well as to guide secondgeneration of more effective and safe therapeutics.

The BEFuture seeks to leverage talent, innovation and technology in support of the transformation of Europe’s MICE tourism sector into a regenerative, resilient and responsible industry. To this end, the project will work to engage the entire MICE ecosystem in the co-design… Read more of a new business model of events for Europe. Events that minimise their waste and carbon footprint, that are sustainable, inclusive and with positive and lasting impact. For that, it will set an open innovation space and network that generates ideas and exchanges knowledge for future industry growth. Using the Sustainable Development Goals framework, the project will identify best practices, and then develop talent, and build innovation capacity among SMEs and industry professionals, organising co-creation workshops and other innovation events that explore technologies, strategies, and trends, and bring together the people and professionals who will shape the future of the industry. Further, to bring forward this new generation of events, BEFuture will roll out an acceleration programme that will support at least 80 innovative projects from Belgium, France, Germany, Italy, Spain and the Netherlands, and a comprehensive communication and awareness-raising campaign, which will take advantage of major industry events such as the IBTM World, IMEX, and Mobile World Congress, amongst other. Overall, the project will contribute to strengthen the competitiveness of the European MICE tourism sector and turn Europe into a global benchmark of innovation, technology, and sustainability of the events’ industry. This enticing project is led by the Catalan Tourist Board, in coordination with Visit Flanders, BSOs such as Linkeus, VDVO and B.Link, and knowledge entities such as NHL Stenden – ETFI and University of Milano-Bicocca. Tipik will be the communication leader. BEFuture holds support from a wide network of ecosystem stakeholders, including Convention Bureaus, BSOs and international industry associations

Beyond-COVID (BY-COVID) aims to provide comprehensive open data on SARS-CoV-2, and other infectious diseases across scientific, medical, public health and policy domains. The project will have a strong emphasis on mobilising raw viral sequences, helping to identify and monitor the spread of… Read more SARS-CoV-2 variants. It will further accelerate access to and linking of data and metadata on SARS-CoV-2 and COVID-19, enable federated data analysis conform with data protection regulations, and harmonisation and management of meta-data and sample- identifiers, as well as long-term cataloguing to ensure interoperability of national and global efforts. BY-COVID will align with the One-Health approach building on the latest technological advances, exploiting and contributing to the European Open Science Cloud capabilities for data access and federation as well as relevant standards and policies for managing, sharing and reusing research data, and work closely with the proposal funded through the sibling-topic from the emergency call (HORIZON-INFRA-2021- EMERGENCY-02). BY-COVID will integrate established national and European infrastructures including ELIXIR, BBMRI, ECRIN, PHIRI and CESSDA. It will build on existing efforts, such as the COVID-19 Data Platform and the Versatile emerging infectious disease observatory project (VEO), thereby maximising efficiency. Synergies with the European Health Data Space will be developed. BY-COVID is a truly interdisciplinary (55 partners from 19 countries) project bringing together stakeholders from the biomedical field, hospitals, public health, social sciences and humanities in an unprecedented and unique effort and will increase European readiness for future pandemics enhance genomic surveillance and rapid-response capabilities. The outputs of the project will allow scientists across multiple domains, including SMEs and industry, to access a range of data that will generate new knowledge on infectious disease.

The FANTOM Doctoral Network (DN) composed of 8 beneficiaries and 12 associated partners in 6 EU countries, recruiting 10 researchers and will be embedded into an established international research programme: The European Research Initiative on Anaplastic Lymphoma Kinase (ALK)-related malignancies… Read more (ERIA) as well as a clinical network: The European Intergroup for Childhood Non-Hodgkin Lymphoma (EICNHL). FANTOM will cosset and nurture the recruited researchers to become confident, competent, independent and well-connected European scientists with excellent career perspectives welcomed into these established networks. This will be achieved through a training programme conducted through research and complemented by a balanced programme of transferable skills designed with key input from both academic and industrial collaborators. The training of each fellow will be guided by an individual career development plan and supervised by a PhD committee with clearly allocated academic and industrial supervisors. The primary goal of the network is to train the recruited fellows by participation in an internationally competitive research programme and integrating them into the aforementioned networks. The research programme will address the clinical problems posed by Anaplastic Large Cell Lymphoma (ALCL) typified by aberrant ALK expression. Applying innovative model systems and multi-omics technologies, some performed to a single cell level, the biology of ALCL including the roles of the immune system and tumour stroma will be uncovered. These data will be applied to the development of (non-invasive) biomarkers and novel therapeutic approaches that will culminate in the design of clinical trials to address the issues of chemotherapy toxicity, over-treatment and drug resistance. The research and training activities will incorporate not only academic labs but also key research institutes, biotechnology companies, clinical trial bodies and Pharma to realise our research goals.